Guardian Pharmacy Services
Guardian Pharmacy Services' revenue rose 17.9% to $1.4 billion in fiscal 2025. Its operating margin was 5.0%, up from −5.1% a year earlier. Free cash flow was $87 million, up 100.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Guardian Pharmacy Services does
Guardian Pharmacy Services supplies medicines and related services to residents of long-term care facilities. It focuses on assisted living facilities, behavioral health facilities and group homes, which tend to be lower-acuity settings. It also serves residents of skilled nursing facilities. It provides prescription filling and delivery plus technology-enabled services meant to help residents stay on their drug regimens.
At the end of 2025 it had 61 pharmacies, 54 of them full-service, serving about 205,000 residents in about 8,400 facilities across 38 states. Its revenue comes from dispensing drugs to those residents, paid through health plans, government programs such as Medicare Part D and the residents themselves. More than two-thirds of its revenue in each of the past three years came from residents of assisted living and behavioral health facilities.
Guardian says these facilities need extra coordination because residents are on many different benefit plans, often have no on-site medical staff, and can choose their own pharmacy, so one facility may use several pharmacies.
Its biggest risks, as it describes them
- Intense competition could cut its profit margins.
- Losing its relationships with drug wholesalers or manufacturers.
- Failing to keep its contracts and relationships with the facilities it serves.
- Changes to Medicare Part D, and any failure to follow Medicare and Medicaid rules.
- Inflation and higher labor costs could reduce profit.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | 5 | 66 |
| Debt incl. finance leases | 7 | 8 |
| Net debt (negative means net cash) | 2 | −58 |
| Net debt to EBITDA | — | −0.6x |
| Debt to equity | 0.1x | 0.0x |
| Interest coverage | −19.2x | 109.3x |
| Current ratio | 1.1x | 1.4x |
| Quick ratio | 0.8x | 1.1x |
Cash flow
Projections
Project Guardian Pharmacy Services' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $99,786 of Guardian Pharmacy Services shares on the open market, and 7 insiders sold $207.3 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 20, 2026 | William E BindleyDirector, 10% owner | Sold | 3,570,677 | $29.68 | $106.0 million | Form 4 |
| Mar 20, 2026 | John AckermanDirector | Sold | 1,103,364 | $29.68 | $32.7 million | Form 4 |
| Mar 20, 2026 | Pharmacy Investors LLCMember of 10% owner group | Sold | 827,636 | $29.68 | $24.6 million | Form 4 |
| Mar 20, 2026 | Fred BurkeSee Remarks, Director | Sold | 671,432 | $29.68 | $19.9 million | Form 4 |
| Mar 20, 2026 | Kendall ForbesSee Remarks | Sold | 346,672 | $29.68 | $10.3 million | Form 4 |
| Mar 20, 2026 | Cardinal Equity Fund L.P.Member of 10% owner group | Sold | 275,728 | $29.68 | $8.2 million | Form 4 |
| Mar 20, 2026 | David K MorrisSee Remarks, Director | Sold | 187,855 | $29.68 | $5.6 million | Form 4 |
| Dec 3, 2025 | Steven D CoslerDirector | Bought | 3,370 | $29.61 | $99,786 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY25 |
|---|---|
| Piotroski F-score | — |
| Rule of 40 | 23.9% |
| Altman Z'' | 3.85 |
| Accruals ratio | −13.9% |
The nine F-score tests
| Test | FY25 |
|---|---|
| Net income is positive | Pass |
| Cash from operations is positive | Pass |
| Return on assets rose | — |
| Cash from operations exceeds net income | Pass |
| Debt fell relative to assets | — |
| Current ratio rose | Pass |
| Share count didn't rise | — |
| Gross margin rose | Pass |
| Revenue rose relative to assets | — |
| F-score | — |
Compare
Put Guardian Pharmacy Services side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Guardian Pharmacy Services | FY25 | 17.9% | 5.0% | 6.0% | 31.0% | −0.6x | — | |
| Lifestance Health | FY25 | 13.8% | 1.7% | 7.7% | 1.2% | 0.5x | 7 | Compare |
| Addus HomeCare | FY25 | 23.2% | 9.7% | 7.3% | 9.4% | 0.2x | 5 | Compare |
| Progyny | FY25 | 10.4% | 6.6% | 14.9% | — | — | — | Compare |
| Tempus AI | FY25 | 83.4% | −19.9% | −18.8% | — | — | 5 | Compare |
2 years of figures
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | 1,228 | 1,449 |
| Revenue growth | — | 17.9% |
| Gross profit | 244 | 293 |
| Research and development | — | — |
| Operating income | −63 | 73 |
| Net income | −110 | 49 |
| Diluted EPS (US$) | — | — |
| Diluted shares (millions) | — | — |
| Cash flow | ||
| Cash from operations | 58 | 100 |
| Capital expenditure | 15 | 13 |
| Free cash flow | 43 | 87 |
| Dividends paid | 0 | 0 |
| Share buybacks | 0 | 0 |
| Acquisitions | 0 | 0 |
| Stock-based compensation | 132 | 14 |
| Balance sheet at fiscal year end | ||
| Cash and short-term investments | 5 | 66 |
| Debt incl. finance leases | 7 | 8 |
| Total assets | 321 | 413 |
| Total liabilities | 171 | 195 |
| Shareholders' equity | 150 | 218 |
| Margins and ratios | ||
| Gross margin | 19.9% | 20.2% |
| Operating margin | −5.1% | 5.0% |
| Net margin | −9.0% | 3.4% |
| Free cash flow margin | 3.5% | 6.0% |
| Rule of 40 (growth + FCF margin) | — | 23.9% |
| Return on capital | — | 31.0% |
| Return on equity | — | 26.8% |
| Return on assets | — | 13.4% |
| Net debt to EBITDA | — | −0.6x |